Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver

Effects of the Introduction of Modern Immunotherapy on the Outcome of Isolated Limb Perfusion for Melanoma In-Transit Metastases

(2023) Carl-Jacob Holmberg et al.   Cancers

Colorectal cancer-derived small extracellular vesicles induce TGFβ1-mediated epithelial to mesenchymal transition of hepatocytes

(2023) Marzia Pucci et al.   Cancer Cell International

Isolated limb perfusion for locally advanced melanoma in the immunotherapy era

(2022) E.J. Davies et al.   EJSO

Uveal Melanoma Exosomes Induce a Prometastatic Microenvironment through Macrophage Migration Inhibitory Factor

(2022) Grazia Ambrosini et al.   MOLECULAR CANCER RESEARCH

The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study

(2022) Carl-Jacob Holmberg et al.   EUROPEAN JOURNAL OF CANCER

Association of tumor molecular factors with in‐transit metastasis in primary cutaneous melanoma

(2022) James W. Jakub et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040

(2022) Melina Arnold et al.   JAMA Dermatology

FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).

(2022) Jonathan S. Zager et al.   JOURNAL OF CLINICAL ONCOLOGY

The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials

(2021) Roger Olofsson Bagge et al.   MELANOMA RESEARCH

Anti-PD-1 checkpoint blockade improves the efficacy of a melphalan-based therapy in experimental melanoma

(2021) Roberta Kiffin et al.   EJSO

Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases

(2021) Anne Zaremba et al.   EUROPEAN JOURNAL OF CANCER

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

(2021) Paul Nathan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

(2021) Lars Ny et al.   Nature Communications

Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases

(2021) Martijn S. Bethlehem et al.   Cancers

International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients

(2020) Jüri Teras et al.   ANNALS OF SURGICAL ONCOLOGY

Checkpoint inhibitor treatment in patients with isolated in-transit melanoma metastases.

(2020) Lucy Storey et al.   JOURNAL OF CLINICAL ONCOLOGY

Isolated limb infusion: Institutional protocol and implementation

(2020) Michael J. Carr et al.   JOURNAL OF SURGICAL ONCOLOGY

Molecular profiling of driver events in metastatic uveal melanoma

(2020) Joakim Karlsson et al.   Nature Communications

Efficacy of immune checkpoint inhibitors for in-transit melanoma

(2020) Emilia Nan Tie et al.   Journal for ImmunoTherapy of Cancer

Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study

(2020) Timothy J. Kenyon-Smith et al.   EJSO

Uveal Melanoma-Derived Extracellular Vesicles Display Transforming Potential and Carry Protein Cargo Involved in Metastatic Niche Preparation

(2020) Thupten Tsering et al.   Cancers

Absence of Intraocular Lymphatic Vessels in Uveal Melanomas with Extrascleral Growth

(2019) Jackelien van Beek et al.   Cancers

Long–Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis

(2019) John T. Miura et al.   ANNALS OF SURGICAL ONCOLOGY

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

(2019) Caroline Robert et al.   LANCET ONCOLOGY

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

(2019) Robert H. I. Andtbacka et al.   Journal for ImmunoTherapy of Cancer

Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)

(2019) Jason J. Luke et al.   CLINICAL CANCER RESEARCH

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2019) O Michielin et al.   ANNALS OF ONCOLOGY

LBA73SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

(2019) P Nathan et al.   ANNALS OF ONCOLOGY

Isolated limb perfusion with melphalan activates interferon-stimulated genes to induce tumor regression in patients with melanoma in-transit metastasis

(2019) Junko Johansson et al.   OncoImmunology

Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma

(2018) Anne Marie Lane et al.   JAMA Ophthalmology

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade

(2018) Charlotte E. Ariyan et al.   Cancer Immunology Research

Minimally invasive isolated limb perfusion – technical details and initial outcome of a new treatment method for limb malignancies

(2018) Roger Olofsson Bagge et al.   INTERNATIONAL JOURNAL OF HYPERTHERMIA

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

(2018) Christian U. Blank et al.   NATURE MEDICINE

Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients

(2018) Junko Johansson et al.   Frontiers in Oncology

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials

(2017) Mengdong Liu et al.   Oncotarget

Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma

(2016) Lesly A. Dossett et al.   ANNALS OF SURGICAL ONCOLOGY

Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns

(2016) Hans E. Grossniklaus et al.   HUMAN PATHOLOGY

Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases

(2015) Marybeth S. Hughes et al.   ANNALS OF SURGICAL ONCOLOGY

Melphalan, Antimelanoma Immunity, and Inflammation--Letter

(2015) A. Martner et al.   CANCER RESEARCH

Update on primary head and neck mucosal melanoma

(2015) Fernando López et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases

(2015) Jan P. Deroose et al.   MELANOMA RESEARCH

Evidence for the Role of Blue Light in the Development of Uveal Melanoma

(2015) Patrick Logan et al.   Journal of Ophthalmology

Burden of Disease Predicts Response to Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma

(2014) Diego J. Muilenburg et al.   ANNALS OF SURGICAL ONCOLOGY

In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy

(2014) Rebecca L. Read et al.   ANNALS OF SURGICAL ONCOLOGY

Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities – Long-term follow-up of a randomised trial

(2014) Roger Olofsson Bagge et al.   INTERNATIONAL JOURNAL OF HYPERTHERMIA

Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma

(2014) Richard D. Carvajal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Host pigment epithelium-derived factor (PEDF) prevents progression of liver metastasis in a mouse model of uveal melanoma

(2013) John M. Lattier et al.   CLINICAL & EXPERIMENTAL METASTASIS

Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma

(2013) Roger Olofsson et al.   INTERNATIONAL JOURNAL OF HYPERTHERMIA

Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance

(2012) G. Ambrosini et al.   CLINICAL CANCER RESEARCH

Current Trends in Regional Therapy for Melanoma: Lessons Learned from 225 Regional Chemotherapy Treatments between 1995 and 2010 at a Single Institution

(2011) Amanda K. Raymond et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Uveal Melanoma: Trends in Incidence, Treatment, and Survival

(2011) Arun D. Singh et al.   OPHTHALMOLOGY

Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety

(2010) D. Moreno-Ramirez et al.   ONCOLOGIST

Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas

(2010) J. W. Harbour et al.   SCIENCE

Safety and Efficacy of Isolated Limb Infusion With Cytotoxic Drugs in Elderly Patients With Advanced Locoregional Melanoma

(2009) Hidde M. Kroon et al.   ANNALS OF SURGERY

Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis

(2009) Alfredo A. Santillan et al.   ANNALS OF SURGICAL ONCOLOGY

Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion

(2008) Georgia M. Beasley et al.   ANNALS OF SURGICAL ONCOLOGY